Autifony CEO Charles Large will be speaking at the webinar ‘Fragile X syndrome – in pursuit of a cure’ World Fragile X Day, Thurs 22 July 2021 – Full webinar…
Read More
Stevenage 16th April – This weekend Dr Charles Large will present key biomarker efficacy data from a first study of AUT00206 in patients with schizophrenia to the Schizophrenia International Research…
Read More
Stevenage, UK – 04 March 2021 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious nervous system disorders, including schizophrenia, hearing loss, Fragile…
Read More
Stevenage, UK – 26 August 2020 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious nervous system disorders, including hearing disorders and schizophrenia,…
Read More
